Ubiquitination is one of the key posttranslational modifications (PTMs) that target proteins for proteasome-dependent degradation. Ubiquitination is critically involved in various cellular functions including drug resistance. Dysregulation of protein ubiquitination could lead to aberrant expression and activity of proteins, resulting in drug resistance. Accumulating evidence has revealed that targeting ubiquitination and degradation of numerous proteins could be useful for overcoming drug resistance in cancer patients. For example, (Proteolysis Targeting Chimeras) PROTACs have been developed to target protein ubiquitination and degradation for improving the treatment benefit in cancer patients.
In this Research Topic, we welcome Original Research, Review, Mini-review, and Perspective articles, which cover ubiquitination in regulating diverse signaling pathways and key factors to regulate drug resistance. Contents may include:
1. Signaling transduction pathways regulated by ubiquitination to regulate drug resistance
2. Research on ubiquitination and E3 ligases as biomarkers for cancer drug resistance
3. New approaches to target ubiquitination to alleviate drug resistance
4. Targeting ubiquitination and degradation by compounds to enhance drug sensitivity
5. Deubiquitination that regulates drug resistance in cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Ubiquitination is one of the key posttranslational modifications (PTMs) that target proteins for proteasome-dependent degradation. Ubiquitination is critically involved in various cellular functions including drug resistance. Dysregulation of protein ubiquitination could lead to aberrant expression and activity of proteins, resulting in drug resistance. Accumulating evidence has revealed that targeting ubiquitination and degradation of numerous proteins could be useful for overcoming drug resistance in cancer patients. For example, (Proteolysis Targeting Chimeras) PROTACs have been developed to target protein ubiquitination and degradation for improving the treatment benefit in cancer patients.
In this Research Topic, we welcome Original Research, Review, Mini-review, and Perspective articles, which cover ubiquitination in regulating diverse signaling pathways and key factors to regulate drug resistance. Contents may include:
1. Signaling transduction pathways regulated by ubiquitination to regulate drug resistance
2. Research on ubiquitination and E3 ligases as biomarkers for cancer drug resistance
3. New approaches to target ubiquitination to alleviate drug resistance
4. Targeting ubiquitination and degradation by compounds to enhance drug sensitivity
5. Deubiquitination that regulates drug resistance in cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
